Exelixis Inc Line of Credit Facility, Collateral Fees, Amount
Exelixis Inc (EXEL) reported Line of Credit Facility, Collateral Fees, Amount of $2.90 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-22.
Discontinued › Notes › Debt
us-gaap:LineOfCreditFacilityCollateralFeesAmount · last filed 2012-02-22
- Exelixis Inc line of credit facility, collateral fees, amount for fiscal 2011 was $2.90M, a 43.14% decline from fiscal 2010.
- Exelixis Inc line of credit facility, collateral fees, amount for fiscal 2010 was $5.10M.
| Period end | Line of Credit Facility, Collateral Fees, Amount 12 month |
|---|---|
| 2011-12-31 | $2.90M 10-K · filed 2012-02-22 |
| 2010-12-31 | $5.10M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |